Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunovia AB ( (SE:IMMNOV) ) just unveiled an announcement.
Immunovia’s interim report for April-June 2025 highlights the company’s strategic advancements and financial performance. The PancreaSure test has been embraced by leading pancreatic cancer centers and is set for a U.S. commercial launch. Despite financial losses due to exchange rate effects, the company has managed to reduce its cash burn rate. Recent achievements include securing a CPT code for Medicare reimbursement, receiving a prestigious award, and announcing a rights issue to support future operations.
More about Immunovia AB
Immunovia AB is a company specializing in the early detection of pancreatic cancer through innovative diagnostic solutions. Their primary product, PancreaSure, is a next-generation blood-based test aimed at identifying pancreatic cancer at an early stage, with a focus on high-risk surveillance programs.
Average Trading Volume: 8,195,400
Technical Sentiment Signal: Buy
Current Market Cap: SEK293.8M
For an in-depth examination of IMMNOV stock, go to TipRanks’ Overview page.